ALBUMINURIA AS A MARKER OF ENDOTHELIAL DYSFUNCTION AND EARLY PREDICTOR OF CARDIOVASCULAR COMPLICATION IN PATIENTS WITH DIABETES MELLITUS

Authors

  • Kravchun N. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Zemlianitsyna O. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Cherniavskaya I. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Karachentsev Yu. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2016.3.01

Keywords:

diabetes mellitus, albuminuria, endothelial dysfunction, non-alcoholic fatty liver disease, treatment.

Abstract

The necessity to identify was grounded and assesses the dynamics of albuminuria and glomerular filtration rate in patients with type 1 and type 2 diabetes (as an early marker of endothelial dysfunction and a predictor of cardiovascular complication) on the background of pathogenetic therapy with glycosaminoglycans sulodexide was done. Clinically significant reduction in the excretion of both total protein and albumin in the urine was found. It indicates an improvement of microcirculation in the kidney along with an increase in glomerular filtration rate. The increase in the glomerular filtration rate is most pronounced in patients with type 2 diabetes with comorbid non-alcoholic fatty liver disease.

References

Dei Cas A, Khan SS, Butler J, et al. JACC Heart Fail 2015; 3:136-145.

Aguilar D, Deswal A, Ramasubbu K, et al. Am J Cardiol 2010; 105:373-377.

McCullough PA, Haapio M, Mankad S, et al. Nephrol Dial Transplant 2010; 25:1777-1784.

McAliste FA, Stewart S, Ferrua S, McMurray JJ. J Am Coll Cardiol 2004; 44:810-819.

Muhin NA, Moiseev VS. Vestnik RAMN 2003; 11:50-55.

Ronco G, et al. Eur Heart J 2010; 31:703-711.

Chernjavskij VV. Novosti Mediciny i Farmacii 2011; 4:354.

Targher G, et al. N Engl J Med 2010; 363:1341-1350.

Sinha A, Rajan M, Hoerger T, Pogach L. Diabetes Care 2010; 33:695-700.

Bennett PH, Haffher S, Kasiske BL, et al. Amer J Kidney Dis 1995; 25(2):107-112.

Mogenstein CE, Keane WF, Bennett PH, et al. Lancet 1995; 346(8982):1080-1084.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee of the Canadian Dia betes Advisory Board. Canadian Diabetes Association. Can J Diabetes 2013; 37: 212 p.

Koskinen J, Kahonen M, Viikari J, et al. Circulation 2009; 120(3):229-236.

Bramlage P, Thoenes M, Kirch W, Lenfant C. Curr Med Res Opin 2007; 23:783-791.

Bramlage P, Böhm Mi, Volpe M, et al. J Clin Hypertens 2010; 12(9):666-677.

Must A, Spadano J, Coakley E, et al. JAMA 1999; 282:1523-1529.

Vanmolkot F, de Hoon J. BMC Neurol 2010; 10:119.

Volpe M. Int J Clin Pract 2008; 62(1):97-108.

Sigitova ON, Arhipov EV. Vestn Sovremen Klinich Mediciny 2014; 7(1):103-106.

Jensen JS, Feldt-Rasmussen BE, Strandgaard S, et al. Ugeskr Laeger 2002; 164(32):3773-3777.

Wachtell K, Ibsen H, Olsen MH, et al. Ann Intern Med 2003; 139:901-906.

Olsen MH, Wachtell K, Tuxen C, et al. J Hypertens 2004; 22(8):1597-1604.

The Heart Outcome Prevention Evaluation Study Investigators. Engl J Med 2000; 342:145-153.

Vaur L, Gueret P, Lievre M, et al. Diabetes Care 2003; 26(3):855-860.

Hillege HL, Fidler V, Diercks GF, et al. Circulation 2002; 106(14):1777-1782.

Hillege HL, Nitsch D, Pfeffer MA, et al. Circulation 2006; 113(5): 671-678.

Shohaimi S, Bingham S, Welch A, et al. Eur J Clin Nutr 2004; 58(10):1432-1435.

Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Circulation 2004; 110(1):32-35.

Bolhovitina OA, Pavlova TV, Poljakov VI, et al. Med Nauki 2011; 6:8-13.

Shestakova MV. RMZh 2001; 9(2):88.

Shishkin A. Vrachebnye Vedomosti 2008; 3(45)6-19.

Liese AD, Hense HW, Brown AA, et al. J Hum Hypertens 2001; 15:799-804.

Moss MB, Siqueira MA, Mann GE, et al. Clin Exp Pharmacol Physiol 2010; 37(2):167-172.

Dzau VJ. Hypertension 2001; 37:1047.

Cai H, Harrison DG. Circ Res 2000; 87:840.

Galle J, Heermeier K. Nephrol Dial Transplant 1999; 14:2585-2589.

Rubanyi GM, Vanhoutte PM. Am J Physiol 1986; 250:822-827.

Harrison DG. Clin Cardiol 1997; 20:11-17.

Pueyo ME, Gonzalez W, Nicoletti A, et al. Arterioscler Thromb Vasc Biol 2000; 20:645.

Seely EW. J Clin Endocrinol Metab 1999; 84(6):1858-1861.

Zakaria AS, Rossetti L, Cristina M, et al. Surg Obes Relat Dis 2015; 15:1550-7289.

Van Dam RM, Dekker JM, Nijpels G, et al. Diabetologia 2004; 47(12):2152-2159.

Gambaro G, van der Woude FJ. J Am Soc Nephrol 2000; 11(2):359-368.

Gaddi AV, Cicero AF, Gambaro G. Int J Nephrol Renovasc Dis 2010; 3:99-105.

Poiubicska A, Staniszewski R, Baum E, et al. Adv Med Sci 2013; 58(2):304-310.

Hoppensteadt DA, Fareed J. Int Angiol 2014; 33(3):229-235.

Li R, Xing J, Mu X, et al. Drug Des Devel Ther 2015; 9:6275-6283.

Levey AS, Stevens LA. Am J Kidney Dis 2010; 55(4):622-627.

Downloads

Published

2021-08-17

How to Cite

Kravchun, N. A., Zemlianitsyna, O. V., Cherniavskaya, I. V., & Karachentsev, Y. I. (2021). ALBUMINURIA AS A MARKER OF ENDOTHELIAL DYSFUNCTION AND EARLY PREDICTOR OF CARDIOVASCULAR COMPLICATION IN PATIENTS WITH DIABETES MELLITUS. Problems of Endocrine Pathology, 57(3), 7-16. https://doi.org/10.21856/j-PEP.2016.3.01

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 5 > >>